IL6 and rheumatoid arthritis: The new formulation developed for SSZ as PLGA MPs prepared with α-tocopherol produced a decrease in IL-1, IL-6 and TNF-α levels thereby resulting in an adequate delivery system for the treatment of chronic inflammatory diseases such as rheumatoid arthritis.